Cantor Fitzgerald Predicts Cybin FY2026 Earnings

Cybin Inc. (NYSE:CYBN - Free Report) - Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for Cybin in a report issued on Monday, June 9th. Cantor Fitzgerald analyst P. Stavropoulos expects that the company will post earnings per share of ($5.94) for the year. Cantor Fitzgerald has a "Strong-Buy" rating on the stock. The consensus estimate for Cybin's current full-year earnings is ($4.76) per share.

Several other equities research analysts have also recently issued reports on the stock. Guggenheim began coverage on shares of Cybin in a research report on Thursday, March 13th. They set a "buy" rating and a $35.00 price objective for the company. HC Wainwright dropped their price target on shares of Cybin from $190.00 to $150.00 and set a "buy" rating for the company in a research note on Thursday, February 13th. Finally, Canaccord Genuity Group reduced their price target on shares of Cybin from $86.00 to $73.00 and set a "buy" rating on the stock in a research report on Wednesday, February 12th.

Cybin Stock Performance

Shares of NYSE CYBN traded down $0.13 during trading on Wednesday, hitting $8.58. 97,933 shares of the company were exchanged, compared to its average volume of 262,842. The company has a fifty day moving average price of $7.11 and a 200-day moving average price of $8.30. The firm has a market capitalization of $196.57 million, a PE ratio of -1.96 and a beta of 0.68. Cybin has a 12-month low of $4.81 and a 12-month high of $13.88.

Institutional Trading of Cybin

Institutional investors and hedge funds have recently bought and sold shares of the stock. National Bank of Canada FI boosted its stake in shares of Cybin by 3,546.5% in the first quarter. National Bank of Canada FI now owns 5,251 shares of the company's stock valued at $33,000 after purchasing an additional 5,107 shares during the period. Global Retirement Partners LLC acquired a new stake in Cybin during the 4th quarter worth approximately $46,000. Marshall Wace LLP purchased a new position in Cybin in the 4th quarter valued at approximately $94,000. Cowa LLC acquired a new position in shares of Cybin in the fourth quarter worth $115,000. Finally, Essential Planning LLC. purchased a new stake in shares of Cybin during the fourth quarter worth $138,000. 17.94% of the stock is currently owned by hedge funds and other institutional investors.

Cybin Company Profile

Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds.